Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Angle Edges Closer To US FDA Clearance For Liquid Biopsy System

Executive Summary

Angle is moving closer to becoming the first company to receive US FDA-clearance for a system that captures and harvests intact circulating tumor cells from patient blood for analysis.

You may also be interested in...

Angle Targets March For US FDA De Novo Submission

Following a Q-submission meeting with the US FDA, liquid biopsy firm Angle says it is in a strong position to progress a de novo submission for the Parsortix system by end of Q1.

Abbott Strikes Deal With British Liquid Biopsy Company Angle

Abbott and UK-based Angle plc announced they will collaborate on a breast cancer liquid biopsy study, assessing Angle's technology for harvesting circulating tumor cells in combination with Abbott's FDA-approved gene-based test for determining HER-2 status.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts